Bone Biologics Corp — Investor Relations & Filings

Bone Biologics Corp. is a medical device company focused on developing therapeutics for bone regeneration. The company's core technology is NELL-1, a proprietary recombinant human protein growth factor designed to enhance orthopedic care. Its lead product candidate, NB1, combines rhNELL-1 with a demineralized bone matrix to function as a bone graft substitute. The primary application for NB1 is in spinal fusion procedures, aiming to provide rapid, specific, and guided bone regeneration. Preclinical studies suggest NELL-1 enhances both the quantity and quality of bone, accelerates healing, and forms bone only in targeted areas without causing inflammation or unwanted bone formation. The company is conducting a pilot clinical study for NB1 in spine fusion patients.